|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1995-1-26
|
|
pubmed:abstractText |
1. Previous work has shown that one mechanism by which blood-borne interleukin-1 alpha (IL-1) may be able to affect the central nervous system (CNS) is by direct transport into the brain across the blood-brain barrier (BBB). The BBB of the brain consists of endothelial (between blood and interstitial fluid) and ependymal (between blood and cerebrospinal fluid) barriers. Which of these barriers IL-1 can cross has not previously been investigated. At the spinal cord, which could be the site of action for some of the effects of IL-1 such as analgesia, the BBB consists only of the endothelial barrier. 2. We show here that IL-1 labelled with 125I (I-IL) is transported across the BBB of the spinal cord by a saturable system similar to the one previously described for the brain. High performance liquid chromatography (HPLC) showed that most of the material entering the spinal cord represented intact I-IL. The BBB of the spinal cord was no more leaky to radioactively labelled albumin than the BBB of the brain and was not disrupted by 50 micrograms kg-1 of IL-1. 3. Capillary depletion showed that most of the I-IL entered the parenchymal-interstitial fluid space of the spinal cord with only a modest amount being sequestered by the endothelial cells of its BBB. 4. I-IL entered the cervical, thoracic and lumbar regions of the spinal cord equally well. I-IL entering at the brain and diffusing caudally was estimated only to account for about 1% of the total radioactivity found in the spinal cord after i.v. injection.(ABSTRACT TRUNCATED AT 250 WORDS)
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1347570,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1360272,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-13950933,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1521930,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1527389,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1698644,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1762091,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1826702,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1852312,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1919601,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-1967907,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-2046463,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-2054614,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-2338547,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-2611685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-2725314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-2784289,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-2804640,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-3258444,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-3260869,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-3499219,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-3528289,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-6822610,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-7514652,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-8096220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-8295729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7799225-8370768
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0022-3751
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
479 ( Pt 2)
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
257-64
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7799225-Animals,
pubmed-meshheading:7799225-Biological Transport,
pubmed-meshheading:7799225-Blood-Brain Barrier,
pubmed-meshheading:7799225-Brain,
pubmed-meshheading:7799225-Chromatography, High Pressure Liquid,
pubmed-meshheading:7799225-Endothelium, Vascular,
pubmed-meshheading:7799225-Injections, Intraventricular,
pubmed-meshheading:7799225-Interleukin-1,
pubmed-meshheading:7799225-Male,
pubmed-meshheading:7799225-Mice,
pubmed-meshheading:7799225-Mice, Inbred ICR,
pubmed-meshheading:7799225-Recombinant Proteins,
pubmed-meshheading:7799225-Spinal Cord
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Blood-borne interleukin-1 alpha is transported across the endothelial blood-spinal cord barrier of mice.
|
|
pubmed:affiliation |
Veterans Affairs Medical Center, New Orleans, LA 70146.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, Non-P.H.S.
|
